ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and InvasionJulie A. Vendrell, Pascale A. Cohen, Ruth Rimokh et al.|Cancer Research|2012Cited by 131
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancerPaul Vilquin, Pascale A. Cohen, Caterina F. Donini et al.|Breast Cancer Research|2015Cited by 79
The critical role of the <scp>ZNF217</scp> oncogene in promoting breast cancer metastasis to the boneAurélie Bellanger, Pascale A. Cohen, Balázs Győrffy et al.|The Journal of Pathology|2017Cited by 55
ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cellsAurélie Thollet, Pascale A. Cohen, Julie A. Vendrell et al.|Molecular Cancer|2010Cited by 51
Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of <i>de novo</i> or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitorPaul Vilquin, Pascale A. Cohen, Marie Villedieu et al.|International Journal of Cancer|2013Cited by 47